AU2020378282B2 - Dual IL-2R and IL-7R binding compounds - Google Patents

Dual IL-2R and IL-7R binding compounds Download PDF

Info

Publication number
AU2020378282B2
AU2020378282B2 AU2020378282A AU2020378282A AU2020378282B2 AU 2020378282 B2 AU2020378282 B2 AU 2020378282B2 AU 2020378282 A AU2020378282 A AU 2020378282A AU 2020378282 A AU2020378282 A AU 2020378282A AU 2020378282 B2 AU2020378282 B2 AU 2020378282B2
Authority
AU
Australia
Prior art keywords
seq
ligand
amino acid
formula
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020378282A
Other languages
English (en)
Other versions
AU2020378282A1 (en
Inventor
Alice V. Bakker
Ronald W. Barrett
Steven E. Cwirla
William J. Dower
Michael C. Needels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medikine Inc
Original Assignee
Medikine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medikine Inc filed Critical Medikine Inc
Publication of AU2020378282A1 publication Critical patent/AU2020378282A1/en
Application granted granted Critical
Publication of AU2020378282B2 publication Critical patent/AU2020378282B2/en
Priority to AU2023214299A priority Critical patent/AU2023214299A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020378282A 2019-11-05 2020-11-04 Dual IL-2R and IL-7R binding compounds Active AU2020378282B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023214299A AU2023214299A1 (en) 2019-11-05 2023-08-10 Dual IL-2R and IL-7R binding compounds

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962930758P 2019-11-05 2019-11-05
US62/930,758 2019-11-05
US202062969432P 2020-02-03 2020-02-03
US62/969,432 2020-02-03
US202063041158P 2020-06-19 2020-06-19
US63/041,158 2020-06-19
US202063071946P 2020-08-28 2020-08-28
US63/071,946 2020-08-28
PCT/US2020/058969 WO2021092081A1 (en) 2019-11-05 2020-11-04 Dual il-2r and il-7r binding compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023214299A Division AU2023214299A1 (en) 2019-11-05 2023-08-10 Dual IL-2R and IL-7R binding compounds

Publications (2)

Publication Number Publication Date
AU2020378282A1 AU2020378282A1 (en) 2022-06-09
AU2020378282B2 true AU2020378282B2 (en) 2023-05-18

Family

ID=75686972

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020378282A Active AU2020378282B2 (en) 2019-11-05 2020-11-04 Dual IL-2R and IL-7R binding compounds
AU2023214299A Abandoned AU2023214299A1 (en) 2019-11-05 2023-08-10 Dual IL-2R and IL-7R binding compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023214299A Abandoned AU2023214299A1 (en) 2019-11-05 2023-08-10 Dual IL-2R and IL-7R binding compounds

Country Status (11)

Country Link
US (2) US11248030B2 (enExample)
EP (1) EP4055036A4 (enExample)
JP (2) JP7427287B2 (enExample)
KR (1) KR20220110209A (enExample)
AU (2) AU2020378282B2 (enExample)
BR (1) BR112022008750A2 (enExample)
CA (1) CA3160466A1 (enExample)
IL (1) IL292803A (enExample)
MX (1) MX2022005404A (enExample)
TW (1) TW202132330A (enExample)
WO (1) WO2021092081A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021201047B2 (en) * 2018-08-06 2022-02-17 Medikine, Inc. Il-2 receptor binding compounds
BR112021002250A2 (pt) * 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
JP7427286B2 (ja) * 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
IL292803A (en) * 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
CA3166816A1 (en) * 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
CA3197344A1 (en) * 2020-11-04 2022-05-12 William J. Dower Il-2r.beta.yc binding compounds and uses thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) * 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054874A1 (en) * 2022-09-06 2024-03-14 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing
WO2024054870A1 (en) * 2022-09-06 2024-03-14 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166163A1 (en) * 2001-12-04 2003-09-04 Emd Lexigen Research Center Corp. Immunocytokines with modulated selectivity
WO2010099084A2 (en) * 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
US20110243887A1 (en) * 2003-12-30 2011-10-06 Merck Patent Gmbh Il-7 fusion proteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
ATE500267T1 (de) * 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CA2820956C (en) 2010-12-10 2016-05-03 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
CN102775496B (zh) * 2011-05-13 2014-10-08 中国医学科学院基础医学研究所 靶向清除hiv/siv的复合药物
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
PT3172227T (pt) 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2017213659B2 (en) 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
CN109562143A (zh) * 2016-05-06 2019-04-02 王牧林 白细胞介素组合及其用途
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators
BR112021002250A2 (pt) 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
IL292803A (en) * 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166163A1 (en) * 2001-12-04 2003-09-04 Emd Lexigen Research Center Corp. Immunocytokines with modulated selectivity
US20110243887A1 (en) * 2003-12-30 2011-10-06 Merck Patent Gmbh Il-7 fusion proteins
WO2010099084A2 (en) * 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules

Also Published As

Publication number Publication date
CA3160466A1 (en) 2021-05-14
US11248030B2 (en) 2022-02-15
BR112022008750A2 (pt) 2022-07-19
IL292803A (en) 2022-07-01
US20220119465A1 (en) 2022-04-21
KR20220110209A (ko) 2022-08-05
JP2024056696A (ja) 2024-04-23
EP4055036A1 (en) 2022-09-14
MX2022005404A (es) 2022-09-09
AU2023214299A1 (en) 2023-10-26
JP7427287B2 (ja) 2024-02-05
US20210130424A1 (en) 2021-05-06
TW202132330A (zh) 2021-09-01
JP2022553826A (ja) 2022-12-26
WO2021092081A1 (en) 2021-05-14
AU2020378282A1 (en) 2022-06-09
EP4055036A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
AU2020378282B2 (en) Dual IL-2R and IL-7R binding compounds
US20230331801A1 (en) Il-2r-beta-gamma binding compounds
US11965015B2 (en) IL-7R-α-γ binding compounds
EP4268901A2 (en) Il-2r beta-gamma c binding compounds and uses thereof
US20220119492A1 (en) Il-2r-beta-gamma binding compounds and uses thereof
CN116829579A (zh) Il-2r和il-7r双重结合化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)